Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Ropivacaine is indicated in adult patients for the induction of regional or local anesthesia for surgery or acute pain management.
UC Davis Health, Sacramento, California, United States
Womack Army Medical Center (WAMC), Fort Bragg, North Carolina, United States
Landstuhl Regional Medical Center (LRMC), Landstuhl, Germany
Tripler Army Medical Center (TAMC), Honolulu, Hawaii, United States
London Health Sciences Centre, St. Joseph's Heath Care, London, Ontario, Canada
Zhongnan hospital, Wuhan, Hubei, China
ZUH, Roskilde, Danmark, Denmark
University of Vermont Medical Center, Burlington, Vermont, United States
Universidad Autonoma de Nuevo Leon, Monterrey, Nuevo Leon, Mexico
Hopital Erasme, Bruxelles Capitale, Belgium
Alberta Children's Hospital, Calgary, Alberta, Canada
The Ottawa Hospital, General Campus, Ottawa, Ontario, Canada
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.